Patients with previously treated non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation experienced clinical benefit from the oral KRAS G12D inhibitor zoldonrasib, according to results presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, held April 25–30.